Limited topical spironolactone evidence does not come from adults with persistent acne. It comes from five small trials with 195 total patients, mostly women ages 11-40 with mild-to-moderate acne vulgaris.
Topical spironolactone means the drug applied to skin as a cream, gel, solution, or powder. Adult persistent acne means acne that continues past the teen years into adulthood. Those trials did not enroll that adult group as a defined cohort.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the five trials tested
- Who was actually studied
- What improved and what did not
- Who was not studied
- What to discuss for persistent adult acne
What the five trials tested
The Journal of Clinical and Aesthetic Dermatology summarizes five trials testing 5% cream, 5% gel, 2% solution, 3% powder, and 1% nanogel formulations in its topical hormonal therapies review. Each trial used a different strength and base. No single product or dose has repeated testing.
Dove Medical Press hosts a narrative review titled Oral and Topical Spironolactone in Adult Female Acne comparing systemic and local approaches. That review frames topical use as an alternative to pills. It does not create new topical trial data.
Who was actually studied
The Journal of Clinical and Aesthetic Dermatology reports the 195 patients ranged from 11 to 40 years old. The group included 152 women and 43 others. Most had mild-to-moderate acne vulgaris.
That mix blends teens with adults. It blends women with men and boys. It does not isolate women over 18 with ongoing facial acne.
What improved and what did not
The Journal of Clinical and Aesthetic Dermatology reports four of the five small trials found significant drops in acne severity index or total lesion count. Adverse events were generally few.
One randomized trial example shows the limit. The PubMed record for the trial reports 5% spironolactone gel twice daily cut total lesion count but did not change acne severity index versus placebo in its J Dermatolog Treat summary. Lesion counts and severity scores can move in different directions.
Who was not studied
Adults with persistent acne were not defined or tracked as a group. No trial required adult age, long duration, or failure of standard care. Readers with year-after-year adult breakouts will not see themselves in the 195.
Larger pooled numbers do not fix the gap. The Dove Medical Press review cites a 14-study, 1,086-patient meta-analysis that mixed oral and topical forms and was not limited to adult women. Pooling adds size without adding adult-specific proof.
What to discuss for persistent adult acne
Strong oral evidence looks different. The NIHR and PMC SAFA report enrolled over 400 women over 18 with facial acne for at least 6 months warranting oral antibiotics, testing oral spironolactone plus standard topical care versus placebo in the full SAFA report.
That design names adult age, duration, and prior-care need. Compounded topical spironolactone is not FDA-approved and has not been FDA-reviewed for acne safety or efficacy, so use is off-label based on prescriber judgment, according to Miiskin prescribing information in its topical spironolactone guide. Bring these points to a visit:.
- your age when acne started and how long current breakouts have lasted
- prior topical care and oral antibiotics tried
- whether pregnancy, potassium issues, or other drugs affect oral options
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline